Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy

Castillo-Regalado, Edgar; Ríos, Raquel; Aràjol, Clàudia; Gely, Cristina; Márquez, Lucía; Calafat, Margalida; González-Muñoza, Carlos; Cañete, Fiorella; Mesonero, Francisco; Guardiola, Jordi.
Gastroenterol. hepatol. (Ed. impr.) ; 46(3): 164-170, Mar. 2023. ilus, tab
Artigo em Inglês | IBECS (Espanha) | ID: ibc-217438

Documentos relacionados

  1. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
  2. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
  3. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
  4. 5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
  5. A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype.
  6. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
  7. COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
  8. 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists.
  9. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
  10. Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.